ArticlePediatric research2026
Gastrointestinal safety of oral erythromycin, clarithromycin, and azithromycin in pediatric patients: a FAERS pharmacovigilance study.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the Medical Management of Pediatric Blepharokeratoconjunctivitis.Advances in therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigates the gastrointestinal adverse events (AEs) associated with oral erythromycin, clarithromycin, and azithromycin in pediatric patients using the FAERS database.
methodsA retrospective pharmacovigilance analysis was conducted on FAERS reports from January 2004 to June 2024. Reports involving pediatric patients (<18 years) with gastrointestinal AEs linked to oral macrolides were analyzed. Disproportionality analysis using the reporting odds ratio (ROR) was performed to assess AE signals.
resultsA total of 2179 AE reports were identified from the FAERS database in which oral erythromycin, clarithromycin, or azithromycin served as the primary suspect drugs, and among these, 705 (32.35%) reports involved gastrointestinal AEs. Azithromycin accounted for 57.45% of cases (ROR = 2.07), clarithromycin 36.17% (ROR = 2.10), and erythromycin 6.38% (ROR = 3.17). Vomiting, diarrhea, and nausea were the most frequently reported AEs. Several novel AE signals not listed in drug labels were detected, including lip swelling and gastric hemorrhage. The median onset time for AEs was 0 days for azithromycin and clarithromycin, and 3 days for erythromycin.
conclusionWhile most gastrointestinal AEs align with known drug profiles, newly identified signals warrant further investigation. Due to limitations of spontaneous reporting systems, future cohort studies are needed to validate these findings and enhance pediatric antibiotic safety. IMPACT: This study examined gastrointestinal side effects in children taking three oral macrolide antibiotics (erythromycin, clarithromycin, and azithromycin) using data from the FAERS database. Out of 2179 adverse event reports, nearly one-third involved gastrointestinal issues, with vomiting, diarrhea, and nausea being the most common. Unexpected signals-such as lip swelling and gastric hemorrhage-were also identified, highlighting the need for further research to enhance the safety of these antibiotics in pediatric patients.
Indexed as
Identifiers
40702206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.